Establishment Labs Completes Enrollment in Motiva US IDE Study
Establishment Labs Holdings Inc., which develops breast aesthetics and reconstruction devices, has completed enrollment in the Motiva US IDE clinical study for breast implants.
Establishment Labs Holdings Inc., which develops breast aesthetics and reconstruction devices, has completed enrollment in the Motiva US IDE clinical study for breast implants.
The ISAPS 2025 global survey reports nearly 17.9 million surgical and 17.3 million non-surgical procedures, with eyelid surgery ranking as the most common surgery.